The initial stages of T-cell differentiation are characterized by a progressive commitment to the T-cell lineage, a process that involves the loss of alternative (myelo-erythroid, NK, B) lineage potentials. Aberrant differentiation during these stages can result in T-cell acute lymphoblastic leukemia (T-ALL). However, the mechanisms regulating the initial stages of human T-cell differentiation are obscure. Through loss of function studies, we showed BCL11B, a transcription factor recurrently mutated T-ALL, is essential for T-lineage commitment, particularly the repression of NK and myeloid potentials, and the induction of T-lineage genes, during the initial stages of human T-cell differentiation. In gain of function studies, BCL11B inhibited growth of and induced a T-lineage transcriptional program in T-ALL cells. We found previously unknown differentiation stage-specific DNA binding of BCL11B at multiple T-lineage genes; target genes showed BCL11B-dependent expression, suggesting a transcriptional activator role for BCL11B at these genes. Transcriptional analyses revealed differences in the regulatory actions of BCL11B between human and murine thymopoiesis. Our studies show BCL11B is a key regulator of the initial stages of human T-cell differentiation and delineate the BCL11B transcriptional program, enabling the dissection of the underpinnings of normal T-cell differentiation and providing a resource for understanding dysregulations in T-ALL.
INTRODUCTION
T-cell differentiation is initiated in the human thymus by multilineage CD34+ progenitors that have arrived from the bone marrow (BM). 1 The earliest stages of thymopoiesis are characterized by a gradual commitment to the T-lineage (loss of alternative lineage potentials). 2, 3 Dysregulations during these stages can result in T-cell acute lymphoblastic leukemia (T-ALL);
4-8 thus delineation of mechanisms underlying the early stages of human thymopoiesis is relevant to understanding T-cell leukemogenesis. Functional studies have yielded key insights about the mechanisms underlying murine T-lineage commitment. 9 However, critical immunophenotypic and regulatory differences between murine and human thymopoiesis have been recognized, 2, [10] [11] [12] and there are few studies of the molecular processes mediating human T-lineage commitment. Thus, our understanding of the regulation of the initial stages of human thymopoiesis is incomplete.
CD34+ progenitors comprise o 1% of all human thymocytes. 3 The earliest thymic progenitors (CD34+CD7 − CD1a − ) are multipotent, possessing myelo-erythroid as well as full lymphoid (B, T and NK) potential. Successive stages of T-lineage commitment are marked by the sequential upregulation of CD7 and CD1a, and a progressive loss of alternative (non T) lineage potentials, resulting in the generation of CD34+CD7+CD1a+ cells, the earliest fully T-lineage-committed progenitors, which produce double positive (CD4+CD8+) thymocytes. [1] [2] [3] Bcl11b is a transcription factor whose expression during murine hematopoiesis is restricted to the T and innate lymphoid lineages. 13, 14 Homozygous Bcl11b deletion induces a differentiation arrest during murine thymopoiesis. 13, 15 A germ line BCL11B mutation was recently reported in a human T-cell immunodeficiency syndrome. 16 Somatic BCL11B mutations or deletions have been associated with T-ALL (9-16% of patients), and murine studies suggest a tumor suppressor role for Bcl11b. [17] [18] [19] BCL11B expression is reduced in Early T-cell precursor ALL (ETP-ALL), a T-ALL subtype with a differentiation arrest at an early stage of thymopoiesis, suggesting BCL11B insufficiency may underlie the pathogenesis of ETP-ALL. 7, 20 However, the function of BCL11B in the initial stages of human T-cell differentiation has not been defined. Moreover, the DNA binding targets of BCL11B during thymopoiesis, and thereby its role in the regulation of T-lineage transcription networks, are largely undelineated. As understanding the regulation of the earliest stages of T-cell differentiation is important for the elucidation of T-cell leukemogenesis, we investigated the role of BCL11B in the initial stages of human T-cell differentiation. We show BCL11B is critical for human T-lineage commitment, particularly the induction of T-lineage genes and the repression of NK and myeloid potentials. Important differences were observed between the regulatory actions of BCL11B in humans and mice. Genome-wide analyses demonstrated previously unknown stage-specific BCL11B binding at multiple T-lineage genes, revealing a previously undescribed BCL11B transcriptional program.
MATERIALS AND METHODS

Lentiviral vectors
Polymerase III (U6/H1) or polymerase II (MNDU3) shRNA lentiviruses were used to knockdown (KD) BCL11B (Supplementary Figure 1b; Supplementary Table 1) . The BCL11B expression lentiviral plasmid was made by inserting a PCR amplified BCL11B cDNA sequence from the BCL11B ORF plasmid (ThermoFisher Scientific, Waltham, MA, USA) into the MNDU3-PGK-GFP plasmid.
Primary tissues
Deidentified cord blood (CB), human thymuses, normal BM and a primary relapsed T-ALL (CD34+CD1 − CD2+CD3 − CD5+CD7+CD4 − CD8+cytoplas-mic CD3+intracellular T-cell receptor beta chain+; translocation 1;9, p34; q34) BM sample were obtained via University of California Los Angeles, Hollywood Presbyterian Hospital, Children's Hospital Los Angeles (CHLA), or the Children's Oncology Group (informed consent obtained as per CHLA IRB approved protocols). Primary T-ALL cells were expanded via serial transplantations in NOD/SCID/IL2Rγ − / − (NSG) mice (primagraft cells). 21 Transduction and culture of CB and thymic CD34+ cells CD34+ cells were enriched from CB or human thymuses using magneticactivated cell sorting (MACS, Miltenyi Biotec, San Diego, CA, USA). CD34+ CB cells were transduced with shRNA (multiplicity of Infection (MOI) = 10) lentivirus. CB or thymic CD34+ cells were transduced with BCL11B expression or control lentivirus (MOI = 1). CD34+GFP+lin − CB or CD34 +CD1a − GFP+lin − thymic cells were sorted (fluorescence activation cell sorting, FACS) and then co-cultured with OP9-DLL1 22 or MS5 stroma, respectively. In some KD experiments (experiments 1 and 3), transduced cells were co-cultured with OP9-DLL1 without prior FACS. The medium for OP9-DLL1 co-cultures medium consisted of alpha-MEM (ThermoFisher), 20% fetal bovine serum (FBS, Hyclone, lot no. AXF42576), L-glutamine (2 mM, Cellgro, Manassas, VA, USA), pencillin-streptomycin (0.5 × , CellGro), IL-7 (5 ng/ml) and Flt3 ligand (5 ng/ml). Cells were harvested on day 11-17, counted and analyzed by flow cytometry. To assess alternative lineage potentials of T-cell precursors, populations isolated from CB-OP9-DLL1 cocultures (CD45+GFP+CD7+CD1a − , CD45+GFP+CD7+CD1a+) or primary thymocytes by FACS were plated on the MS5 (murine BM stromal) cell line in: (1) DMEM (ThermoFisher), 10% FBS, L-glutamine, pencillin-streptomycin, 2-mercaptoethanol (50 μM, ThermoFisher), IL-3 (5 ng/ml), Tpo (50 ng/ml), FLT-3 ligand (5 ng/ml), SCF (5 ng/ml), GM-CSF (5 ng/ml) and EPO (4 ng/ml) (myelo-erythroid conditions); (2) RPMI 1640 (ThermoFisher), 5% FBS, L-glutamine, pencillin-streptomycin, 2-mercaptoethanol (50 μM, ThermoFisher), Tpo (5 ng/ml), FLT-3 ligand (5 ng/ml) and IL-7 (5 ng/ml; B/NK conditions); and (3) DMEM, 10% FBS, L-glutamine, pencillin-streptomycin, 2-mercaptoethanol (50 μM), IL-15 (10 ng/ml) and SCF (20 ng/ml) (NK conditions). Cytokines were purchased from Milteyni (except IL-15, GM-CSF and Epo (Peprotech, Rocky Hill, NJ, USA)). Supplementary Table 2 lists FACS antibodies.
Culture, transduction and xenotransplantation of T-ALL cells
Primagraft cells were cultured in alpha-MEM, 20% FBS, L-glutamine and penicillin-streptomycin. MOLT-16 and CCRF-CEM were purchased from ATCC (Manassas, VA, USA) and DSMZ (Braunschweig, Germany), respectively, and cultured as per their recommendations. TP53 mutation testing was done by Sanger sequencing (Supplementary Table 3 ). Cells were transduced with BCL11B expression or control lentivirus (MOI = 1). GFP+ cells isolated by FACS 72 h post transduction were then cultured in vitro, transplanted into sublethally irradiated (250 cGY) 6-9-week-old female NSG mice by tail vein injection (5000-17 000 cells per mouse, age-stratified randomization, sample size not estimated a priori, unblinded) or used for RNA-Seq. Animals were used as per IACUC approved protocols and killed when they developed clinical signs of leukemia.
Western blot
Primary antibodies: Rabbit anti-BCL11B (D6F1, Cell Signaling, Danvers, MA, USA), anti Beta-Actin (Genetex, Irvine, CA, USA), or Anti-alpha Tubulin (EPR13478 (B), Abcam, Cambridge, MA, USA). Secondary antibodies: goat anti-rabbit or anti-mouse HRP-linked IgG (Cell Signaling).
RNA-Seq
The Ovation Human FFPE RNA-Seq System (NuGen, San Carlos, CA, USA) was used to generate amplified cDNA libraries (input = 25 ng RNA extracted using the Qiagen MIrneasy kit, Valencia, CA, USA), which were sequenced on the Illumina Nextseq500 (paired end 75 bp, average of 13 million (from T-cell precursors) or 21 million (from T-ALL cells) paired-end reads per sample, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token = efelwcoqlbwbxcd&acc = GSE84678). Data was analyzed using Tophat, 23 HTSeq, 24 DESeq2 (ref. 25) and GSEA. 26 The methods for differential expression analysis of previously generated RNA-Seq data have been described. 27 ChIP-Seq (chromatin immunoprecipitation followed by deep sequencing) CD34+ and CD34 − cells were isolated from human thymuses by MACS. ChIP was done using anti-Bcl11b or isotype control antibody (Cell Signaling 
RESULTS
BCL11B expression during human thymopoiesis
To assess the expression of BCL11B during human thymopoiesis, we analyzed previously generated RNA-Seq data from BM hematopoietic stem cells (HSC), lymphoid progenitors from the BM and thymus, and CD4+CD8+ (Thy4) cells, the predominant fully T-lineage committed population in the thymus 27, 35 (developmental hierarchy of populations depicted in Figure 1a ). BCL11B was not expressed in BM cells and first became detectable in CD34+ thymic progenitors. A progressive increase in expression was seen with successive stages of T-lineage commitment and differentiation ( Figure 1b) . Similar results were seen with qPCR (Supplementary Figure 1a) . In summary, BCL11B expression is induced early on during T-cell differentiation in the human thymus, and upregulation of BCL11B is associated with T-lineage commitment and subsequent differentiation into CD4+CD8+ cells.
BCL11B is essential for human T-lineage commitment
The role of BCL11B in the initial stages of human T-cell differentiation was investigated through loss of function experiments in multi-lineage CB CD34+ progenitors using the in vitro OP9-DLL1 stromal co-culture system. The earliest stages of T-cell differentiation and commitment in the thymus are recapitulated in the OP9-DLL1 system through the sequential appearance of multilineage CD7+CD1a − and T-lineage restricted CD7+CD1a+ T-cell precursors, the latter emerging at day 10-14 of culture. 22, 36 Although the earliest fully T-lineage committed cells in vivo are CD34+, in the OP9-DLL1 system the induction of CD1a expression and concomitant T-lineage restriction coincide with the loss of BCL11B regulates early human T-cell differentiation VL Ha et al CD34 expression. 36 Hence, the value of CD34 as a phenotypic marker is limited in the context of dissection of commitment during the initial stages of in vitro T-cell differentiation. As our studies were focused on the initial stages of thymopoiesis, we analyzed OP9-DLL1 co-cultures on approximately day 14 of culture to measure differentiation into T-cell precursors, defined as CD7+CD1a − and CD7+CD1a+ cells (Figure 2a) . CB CD34+ cells were transduced with a BCL11B KD or scrambled control lentivirus and then cultured on OP9-DLL1 stroma. Figure 2a) . Also, KD co-cultures showed higher frequency of CD34+ cells with both KD shRNA sequences in two experiments and one of two shRNA sequences in a third experiment (Supplementary Figure 2b) , a finding consistent with an impairment of differentiation in KD co-cultures.
KD of BCL11B decreased cell output (Supplementary Figure 2c) . To verify that BCL11B insufficiency resulted in impaired T-lineage commitment and that the immunophenotypic differences between KD and control co-cultures were not simply due to increased death of CD7+CD1a+ cells in KD co-cultures, we tested whether BCL11B insufficiency had an effect on the alternative (non T) lineage potentials of T-cell precursors. We isolated CD7+CD1a − and CD7+CD1a+ cells from KD and control OP9-DLL1 co-cultures and then re-cultured them in conditions supportive of myeloid, erythroid, B and/or NK lineage differentiation (secondary cultures, Figure 3a ). Cells sorted from KD OP9-DLL1 co-cultures showed robust BCL11B KD (Figure 3b) . Consistent with the association of CD1a expression with T-lineage commitment, control CD7+CD1a+ cells generated substantially lower numbers of NK (CD56+ and CD56+CD11c+ 37 ) and myeloid (CD33+ and CD14/15+) cells relative to those generated by control CD7+CD1a − cells (Figure 3c ). These findings recapitulate the loss in alternative lineage potential seen with CD1a expression in primary thymic progenitors (Supplementary Figure 3a) , validating the secondary cultures as an assay for investigating T-lineage commitment. KD of BCL11B resulted in the generation of significantly higher numbers of NK and myeloid cells in secondary cultures (Figures 3c and d) . Almost no erythroid (CD235+) or B (CD19+) cells were generated in KD or control secondary cultures (data not shown). Of note, the effect of KD on alternative lineage cell outputs significantly varied (P o 0.05) with cell type (CD7+CD1a − or CD7+CD1a+). The more pronounced effects of KD in cultures initiated with CD7+CD1a+ To further investigate the effects of BCL11B on T-lineage commitment, we performed gain of function experiments in uncommitted CD34+ (CD34+CD1a − ) progenitors isolated from human thymuses. In agreement with the increased NK and myeloid output seen with BCL11B insufficiency in the KD experiments, BCL11B overexpression inhibited myeloid and NK potential of thymic CD34+CD1a − progenitors (Supplementary Figure 3b) .
Overall, BCL11B insufficiency impairs T-lineage commitment, in particular prevents the repression of NK and myeloid lineage potential, and induces a differentiation arrest during the initial stages of human T-cell differentiation.
BCL11B overexpression inhibits growth of T-ALL cells To study the effects of BCL11B in T-ALL cells, we transduced T-ALL cells with BCL11B-GFP (overexpressing cells) or control GFP (control cells) lentivirus. T-ALL cells at varying stages of differentiation arrest were used (xenografted cells derived from a CD34+ T-ALL primary sample (primagraft), and CCRF-CEM (pre-T) and MOLT-16 (mature T) CD34 − cell lines, 38 BCL11B protein levels depicted in Supplementary Figure 4a) . Both cell lines and primagraft cells harbored TP53 mutations; 39 a NOTCH1 mutation was present in primagraft cells (Supplementary Table 4) . A low MOI ( = 1) was used to reduce effects secondary to supraphysiologic BCL11B levels ( Supplementary Figures 4b and c) . BCL11B overexpression significantly inhibited the growth of T-ALL cells in vitro (Figure 4a; Supplementary Figure 5a) . The inhibitory effect of BCL11B in leukemic cells was in contrast to its effects in CB CD34+ progenitors, where overexpression did not inhibit cell growth (Supplementary Figure 5b) . BCL11B overexpression significantly increased apoptosis of primagraft cells (Figure 4b ). NSG mice transplanted with overexpressing or control primagraft cells rapidly developed leukemia (median survival time, control vs BCL11B = 40 days vs 41.5 days, P = 0.74). However, overexpression decreased the growth of T-ALL cells after transplantation in terms of cell numbers (Figure 4c; Supplementary Figure 5c ). Also, human T-ALL cells in mice transplanted with overexpressing cells showed a lower proportion of GFP+ cells than control mice (Supplementary Figure 5d ), suggesting intense selection pressure against overexpressing cells. Overall, BCL11B overexpression inhibits growth of T-ALL cells, an effect that can at least be seen in TP53 mutant cells.
BCL11B is required for the establishment of a T-lineage commitment transcriptional program To define the transcriptional effects of BCL11B insufficiency during the initial stages of T-cell differentiation, we performed RNA-Seq on CD7+CD1a − and CD7+CD1a+ cells isolated from control and KD OP9-DLL1 co-cultures. KD cells showed upregulation of Figure 3 . BCL11B is required for T-lineage commitment, particularly the repression of NK and myeloid lineage potentials, during the initial stages of human thymopoiesis. (a) CB CD34+ progenitors were transduced with control (ctrl) or BCL11B KD shRNA lentivirus and then co-cultured with OP9-DLL1 stroma. CD7+1a − (CD1a − ) and CD7+CD1a+ (CD1a+) T-cell precursors generated in these OP9-DLL1 co-cultures were sorted and replated in three different culture conditions that promote alternative (non T, that is, myeloid, erythroid, B and/or NK) lineage differentiation (MS5 stroma co-cultures). (b) BCL11B gene expression in T-cell precursors sorted from OP9-DLL1 co-cultures (N = 3 independent experiments, each done with a different pool of CB donors; expression measured by qPCR relative to that of ACTB; P o0.05 for ctrl CD1a − vs KD CD1a − , P = 0.05 for ctrl CD1a+ vs KD CD1a+). Experiments were done using the KD shRNA sequence s3.
BCL11B regulates early human T-cell differentiation VL Ha et al hematopoietic stem and progenitor (BAALC, GFI1B, HOXA9, CD34) and myeloid (MEF2C, MPO) genes and downregulation of T-lineage genes (PTCRA, RAG1, RAG2, LCK, ZAP70, THEMIS). Also, KD induced upregulation of genes important for NK cell development (DTX1) 12 and function (ZBTB16), 40 and downregulation of IL7R, a gene critical for T-cell differentiation. NOTCH1 signaling is known to be decreased during human T-lineage commitment; 12 KD cells, however, showed upregulation of NOTCH1 target genes (DTX1, NRARP, MYC) 12 (Figures 5a and b) . Overall, KD resulted in downregulation of genes that are normally induced with T-lineage commitment, and the aberrantly sustained expression of a transcriptional program characteristic of the earliest stage of human thymopoiesis (Thy1, CD34+CD7 − CD1a − ; Figures 5a and b;  Supplementary Figures 6a and b) .
We next investigated the transcriptional effects of BCL11B through gain of function studies in cells with a T-lineage differentiation arrest, namely T-ALL cells. 4 Overexpressing and control primagraft T-ALL cells were analyzed by RNA-Seq at 72 h post transduction. We chose this early time point to minimize the impact of proliferation, survival or profound differentiation state differences between cells on gene expression. Control T-ALL cells showed high LYL1, LMO2 and TAL1 expression levels (Supplementary Figure 6c) , an expression pattern characteristic of a subgroup of the LYL1+ T-ALL subtype. 4 To resolve the differences between overexpressing and control cells with respect to transcriptional changes during normal lymphopoiesis, we performed a principal component analysis of normal hematopoietic cell types 27 and these T-ALL cells, using expression values of genes that were differentially expressed between overexpressing and control T-ALL cells (FDR o 0.05, n = 420 genes) (Figure 5c) . Expectedly, the first principal component separated T-ALL cells from normal cells, whereas the second principal component recapitulated the differentiation of early uncommitted BM progenitors (HSC and LMPP) along T-lineage or B-lineage pathways. In particular, the trajectory towards T-lineage differentiation followed increasing values for the second principal component. Strikingly, overexpressing cells and control cells showed a trajectory parallel to that of the early (CD34+) stages of T-lineage differentiation in the thymus, with overexpressing cells being positioned further along the T-lineage pathway than control cells (Figure 5c) . Genes induced during normal T-cell differentiation were upregulated and those genes expressed in early thymic progenitors and repressed during normal T-cell differentiation were downregulated, in T-ALL cells that overexpressed BCL11B (Figure 5d ).
In summary, BCL11B is a key regulator of the T-lineage commitment transcriptional program through the repression of stem, NK and myeloid genes and the upregulation of T-lineage genes.
BCL11B DNA binding during T-cell differentiation
The DNA binding targets of BCL11B in thymic progenitors, and changes in binding during differentiation, remain largely unidentified. To define binding targets, we performed ChIP-Seq for BCL11B on two populations isolated from human thymuses: CD34+ progenitors and the more differentiated CD34 − cells. Consistent with the upregulation of BCL11B expression with differentiation (Figure 1b) , CD34 − cells showed over twice the binding sites seen in CD34+ cells (Figure 6a; Supplementary Table 5) . Almost all sites seen in CD34+ cells were retained in CD34 − cells, and top ranked site motifs were similar in both populations, indicating similar site preferences in both cell types (Supplementary Figure 7a) . Notably, the motif (-GGCCGG-) for the highly homologous transcription factor BCL11A 41 was one of the most significantly enriched motifs (Supplementary Figure 7a) . Most sites were associated with promoters of protein coding or lncRNA genes (Figures 6b and c) , and included the previously reported binding targets, ID2 and P57. 42, 43 To define differentiation stage related differences in binding, we performed differential binding analysis (Supplementary Table 6 ). High inter-replicate reproducibility and distinct binding profiles for the two cell types were observed (Figure 7a; Supplementary  Figure 7b) , indicating global changes in binding with differentiation. Most differentially bound genes showed greater binding in CD34 − cells than in CD34+ cells, indicating an overall gain in binding with differentiation (Figure 7b) .
Genes with greater binding in CD34 − cells were significantly enriched for T-lineage genes ( Supplementary Figure 7c ; Supplementary Table 7) . To investigate the association between binding and expression of target genes, we performed a combined analysis of the ChIP-Seq data and previously generated RNA-Seq data from CD34+ and CD34 − cell types in the thymus.
26
Thy4 cells, which are fully T-lineage committed, constitute a majority of the thymic CD34 − cells.
35 CD34+ thymic cells are almost entirely made up of uncommitted Thy2 (mean = 64.7% of CD34+ thymocytes, s.e.m. = 8.6%, n = 8 thymuses) and fully committed Thy3 cells. 2, 3 Given the continuum of transcriptional changes during thymopoiesis, we selected RNA-Seq data from Thy2 and Thy4 cells for the analysis. We used two approaches previously used to study relationships between binding and expression. 34 First, we classified BCL11B bound genes that were differentially expressed into three groups based on binding Table 8) . Analysis of expression fold change values for these groups showed that overall, increased binding was associated with an upregulation in expression (Figure 7c ). For instance, genes with increased binding in CD34+ cells (NOTCH1, FLT3, ERG) were upregulated in Thy2 cells, and genes with increased binding in CD34 − cells (BCL11B, MTA3, CD8) were upregulated in Thy4 cells (Figure 7d) , a relationship also seen when all bound genes (differentially expressed as well as not differentially expressed) were analyzed (Supplementary Figure 8a) . We next performed a reverse approach, grouping genes based on differential expression (Supplementary Table 8) , and then comparing binding fold changes at differentially expressed genes with those at transcribed genes (that is, genes with open chromatin) that were not differentially expressed (stably expressed genes). Consistent with results from the first approach, overall, genes upregulated in Thy4 cells showed increased binding in CD34 − cells, and genes upregulated in Thy2 cells showed increased binding in CD34+ cells (Figures 7e and f; Supplementary Figures 8b and c) . These findings demonstrate a positive association between BCL11B binding and target gene expression during human thymopoiesis. Furthermore, BCL11B KD resulted in downregulation of genes that showed increased binding with differentiation, suggesting a transcriptional activator function for BCL11B at T-lineage genes (Supplementary Figure 9) .
Overall, BCL11B has numerous binding targets, many of which are differentiation stage specific. Thymopoiesis is characterized by a gain in BCL11B binding at multiple T-lineage genes with differentiation, and binding is associated with upregulation of these genes, many of which show BCL11B-dependent expression. These data further support a critical role for BCL11B in the induction of a T-lineage transcriptional program.
DISCUSSION
Through functional and bioinformatic studies, we here demonstrate BCL11B is essential for T-lineage commitment, binds to key T-lineage genes in a stage-specific manner, and has negative and positive regulatory modes of action during the initial stages of human T-cell differentiation, namely the repression of NK and myeloid potentials and the upregulation of genes critical for T-lineage differentiation.
The requirement of BCL11B for human T-lineage commitment is consistent with findings from murine studies. 13, 44 However, Bcl11b knockout murine pre-commitment progenitors upregulated T-lineage genes normally, suggesting abnormally sustained expression of stem cell genes rather than failure of induction of T-lineage genes accounted for their differentiation arrest. 9 Furthermore, murine knockout cells showed abnormally upregulated Il7r expression. 13 In contrast, human KD cells showed downregulation of key T-lineage genes including IL7R, indicating important species related differences in regulatory effects of BCL11B. These findings add to previously reported species-specific regulatory aspects of thymopoiesis such as differences in the effects of NOTCH1 signaling on human and murine T-lineage commitment. 11, 12 Although the function of BCL11B as a repressor of NK potential is conserved, differences were observed regarding the specific NK associated genes upregulated in human and murine BCL11B-deficient cells isolated from OP9-DLL1 co-cultures. ZBTB16, a gene important for human NK cell function, was upregulated in both species. However, human cells did not show upregulation of TBX21, ID2, ZNF35 or IL2RB, genes whose markedly elevated expression is a hallmark of the NK like signature characteristic of murine cells even in conditions not very permissive of NK differentiation (that is, NOTCH signaling OP9-DLL1 co-cultures without IL-15). 12, 45 Differences in experimental design (KD vs knockout) represent a caveat to the interpretation of these incongruities. Nevertheless, the exquisite sensitivity of these genes to BCL11B insufficiency in mice raises the possibility of species-specific regulatory effects of NOTCH1 or BCL11B on these genes.
Knowledge of BCL11B binding targets has been limited to studies of a few gene promoters, which suggested both transcriptional repressor and activator roles for BCL11B. 42, 46, 47 Binding and expression analyses in primary thymocyte subsets and KD experiments suggested an activator role for BCL11B on the expression of T-lineage genes. Thus, our studies revealed a BCL11B transcriptional program previously undescribed in murine or human thymopoiesis, emphasizing the importance of investigating binding targets in fractionated populations. Further studies are needed to investigate the mechanisms underlying the negative regulatory effects of BCL11B on stem, NK and myeloid genes.
ETP-ALL, a T-ALL subtype reported to have poor outcomes, is characterized by a differentiation arrest at an initial stage of thymopoiesis, upregulation of stem and myeloid genes, and downregulation of T-lineage genes. 20 BCL11B is repressed in ETP-ALL. 7, 20 BCL11B mutations (predicted to be hypofunctional) are seen across T-ALL subtypes with varying degrees of differentiation arrest. 18 Our data on the effects of BCL11B insufficiency on the initial stages of human thymopoiesis strongly support the notion that BCL11B repression at least partly contributes to the aberrant differentiation in ETP-ALL. Furthermore, the stage-specific binding of BCL11B to critical T-lineage genes during thymopoiesis and its role as an inducer of T-lineage genes provide a molecular basis for interpreting dysregulations in T-ALL with BCL11B aberrations. In our studies, BCL11B overexpression in T-ALL cells induced expression of T-lineage genes and inhibited proliferation but did not impact survival of mice transplanted with primary relapsed T-ALL cells. The use of relapsed T-ALL cells with multiple oncogenic aberrations (TP53 and NOTCH1 mutations) that rapidly generated clinical leukemia in recipients, along with the outgrowth of GFP − cells in mice transplanted with overexpressing cells, might account for the lack of effect on survival.
Our studies delineate the regulatory actions of BCL11B critical for the establishment of the T-lineage program during the initial stages of human T-cell differentiation, providing a framework for understanding normal thymopoiesis and aberrations seen in T-ALL and immunodeficiencies.
